Cynvenio Biosystems Shipping First Complete Genomic Testing Solution for Liquid Biopsies in Oncology

Cancer diagnostics company delivers complementary technologies for peripheral monitoring in cancer

LOS ANGELES, January 02, 2015 – Cynvenio Biosystems, Inc. announced today the nationwide availability of its LiquidBiopsy® platform, which utilizes a blood sample to perform sequence analysis and genomic reporting. This platform gives doctors and cancer researchers the ability to perform next-generation sequencing (NGS) on rare populations of circulating tumor cells and cell-free DNA from whole blood. 

Cynvenio’s LiquidBiopsy simultaneously analyzes DNA from circulating tumor cells (CTCs) as well as circulating tumor DNA, which studies have shown help target therapies and track tumor response.   

“Cynvenio has solved the problem of molecularly detecting extremely rare cells in the bloodstream that are known to drive the metastatic process,” said André de Fusco, CEO of Cynvenio.

Cynvenio’s LiquidBiopsy is a turn-key platform for academic and pharma R&D programs in oncology. It was recently selected by Thermo Fisher Scientific for distribution as an integrated solution with their Ion Torrent Next Generation Sequencing Platform for clinical research applications. Cynvenio’s automated rare cell workflow makes it a cost-effective and easy choice for a wide array of personalized cancer research projects, especially those focused on DNA sequencing from blood.

“Our company is dedicated to facilitating a new era of individualized medicine,” de Fusco said. “The LiquidBiopsy system and Thermo Fisher’s next-generation sequencing workflow bring immediate value to translational researchers globally. The time and money normally spent integrating instrumentation and software elements can now be dedicated to research. Labs can be instantly productive with new NGS workflows.” 

Cynvenio’s LiquidBiopsy platform is used to monitor tumor response through the identification of DNA mutations in 50 genes commonly altered in cancer. It is compatible with larger (and smaller) gene panels which can be created as required. LiquidBiopsy is optimized for Thermo Fisher Scientific’s NGS sequencers with full support for other downstream analysis methodologies.   

About Cynvenio Biosystems, Inc.

Cynvenio is a molecular information technology company that helps make individualized cancer treatment possible by providing longitudinal insights into each patient via the genomic analysis of their cancer from a standard blood draw.  Cynvenio’s LiquidBiopsy® clinical assays for solid tumors are used as therapy finders to periodically assess patients’ individual mutations and match them with targeted cancer therapies and clinical trials. The company’s tests complement traditional tissue biopsy analysis or can be used as standalone tests to identify therapies for patients in which tissue biopsy is deemed difficult or too risky to collect.Cynvenio is headquartered in Westlake Village, California (Los Angeles). For more information, visit http://www.cynvenio.com.

LiquidBiopsy® is a registered trademark of Cynvenio Biosystems, Inc.